Jog on, kitties: Circassia publishes cat allergy vaccine data ahead of Phase III
This article was originally published in Scrip
Executive Summary
As Circassia embarks on Phase III testing for its lead ToleroMune allergy treatment in the fourth quarter of this year, the company announced the publication of Phase II data for the cat allergy vaccine.